Form 4: iTeos Therapeutics Chief Medical Officer Receives 47,000 Restricted Stock Units

David Feltquate, Chief Medical Officer of iTeos Therapeutics, was granted 47,000 restricted stock units (RSUs) that will vest on December 6, 2026.

Summary

• David Feltquate, the Chief Medical Officer of iTeos Therapeutics, received 47,000 restricted stock units (RSUs) on December 6, 2024.
• Each RSU represents the right to receive one share of iTeos Therapeutics common stock.
• The RSUs will vest on December 6, 2026, contingent upon Mr. Feltquate's continued employment with the company.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed positively as it aligns management with shareholder interests. There are no negative implications.

Positives

• The grant of RSUs aligns the Chief Medical Officer's interests with the long-term success of the company.
• The vesting schedule encourages continued service and commitment from the executive.

Risks

• The vesting of the RSUs is contingent on continued employment, which could be a risk if the executive leaves the company before the vesting date.

Future Outlook

The granted RSUs will vest in December 2026, subject to continued service.

Industry Context

Stock-based compensation, such as RSU grants, is a common practice in the biotechnology industry to attract and retain key executives.

Comparison to Industry Standards

• RSU grants are a standard form of compensation for executives in the biotech industry, often used to align management's interests with shareholders.
• The vesting period of two years is also typical for such grants, ensuring long-term commitment from the executive.
• Companies like Moderna, BioNTech, and Regeneron also use similar stock-based compensation plans for their executives.

Stakeholder Impact

• The RSU grant aligns the Chief Medical Officer's interests with shareholders, potentially leading to increased focus on long-term value creation.
• Employees may view this as a positive sign of the company's commitment to its leadership.

Key Dates

Keywords

restricted stock units, RSU, stock grant, iTeos Therapeutics, executive compensation, David Feltquate, Chief Medical Officer, vesting